Clinical trials: Liraglutide
Type 1 Diabetes
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
The main objectives of the trial are to study whether daily treatment with liraglutide improves insulin secretion and glucose metabolism, and whether liraglutide treatment is tolerable and safe in subjects with preclinical type 1…
- Trial name
- NCT02611232
- Testing
- Victoza®
- Where
- 3 sites in Finland
- Volunteers
- 42 people
- Sponsor
- University of Oulu
Type 1 Diabetes
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who…
- Trial name
- NCT02898506
- Testing
- Victoza®
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Type 1 Diabetes Mellitus
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.
- Trial name
- NCT03632759
- Testing
- Liraglutide, Golimumab
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Carla Greenbaum, MD
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Anti-diabetic Drugs and Fatty Liver Management
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).
- Trial name
- NCT05041673
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Alexandria University
Type 1 Diabetes
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects…
- Trial name
- NCT02908087
- Testing
- Victoza® (liraglutide)
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks.
- Trial name
- INTENSIFY (NCT03823339)
- Testing
- Insulin degludec/liraglutide
- Where
- 3 sites in United Arab Emirates
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Human Bioequivalence Test of Liraglutide Injection
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so…
- Trial name
- NCT05029076
- Testing
- Liraglutide injection, Victoza
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Treatment of Diabetic Neuropathy With Liraglutide
The purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.
- Trial name
- TODINELI (NCT02138045)
- Testing
- Liraglutide treatment
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Aalborg University Hospital
Diabetes Mellitus, Type 2
A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor.
- Trial name
- VIEW-Iran (NCT03888157)
- Testing
- Liraglutide
- Where
- 16 sites in Iran
- Volunteers
- 839 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
The purpose of this study is to collect information about the safety and effectiveness of Saxenda® in obese patients and overweight patients with obesity-related comorbidities.
- Trial name
- NCT03560336
- Testing
- Liraglutide
- Where
- 28 sites in South Korea
- Volunteers
- 758 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2 diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and only few randomised controlled trials (RCTs)…
- Trial name
- NCT04146155
- Testing
- Liraglutide+standard-of-care treatment, standard-of-care treatment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents…
- Trial name
- Ellipse™ (NCT01541215)
- Testing
- liraglutide, metformin
- Where
- 185 sites in United States, Australia and 34 more
- Volunteers
- 135 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effect of GLP-1 on Angiogenesis
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications…
- Trial name
- ANGIOSAFE 1 (NCT02686177)
- Testing
- Liraglutide, Metformin or sulfonylurea
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Obesity
Reward Mechanisms in Obesity
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes).
- Trial name
- LIRAOB (NCT03347890)
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Zoltan Pataky
Obesity, Obesity, Morbid
Liraglutide for Low-responders After Bariatric Surgery
To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.
- Trial name
- LIBAR (NCT04643301)
- Testing
- Liraglutide Pen Injector
- Sponsor
- Zuyderland Medisch Centrum
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S